These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 22049226)

  • 1. Receptor activator for nuclear factor κ B expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis.
    Zhang L; Teng Y; Zhang Y; Liu J; Xu L; Qu J; Hou K; Yang X; Liu Y; Qu X
    J Clin Pathol; 2012 Jan; 65(1):36-40. PubMed ID: 22049226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-Src expression is predictive of poor prognosis in breast cancer patients with bone metastasis, but not in patients with visceral metastasis.
    Zhang L; Teng Y; Zhang Y; Liu J; Xu L; Qu J; Hou K; Yang X; Liu Y; Qu X
    APMIS; 2012 Jul; 120(7):549-57. PubMed ID: 22716210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer.
    Ohi Y; Umekita Y; Yoshioka T; Souda M; Rai Y; Sagara Y; Sagara Y; Sagara Y; Tanimoto A
    Histopathology; 2011 Oct; 59(4):776-80. PubMed ID: 22014057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
    Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L
    Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
    Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
    J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor activator of nuclear factor-kappaB ligand (RANKL) expression in hepatocellular carcinoma with bone metastasis.
    Sasaki A; Ishikawa K; Haraguchi N; Inoue H; Ishio T; Shibata K; Ohta M; Kitano S; Mori M
    Ann Surg Oncol; 2007 Mar; 14(3):1191-9. PubMed ID: 17195907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
    Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
    J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.
    Castellano I; Allia E; Accortanzo V; Vandone AM; Chiusa L; Arisio R; Durando A; Donadio M; Bussolati G; Coates AS; Viale G; Sapino A
    Breast Cancer Res Treat; 2010 Dec; 124(3):607-17. PubMed ID: 20127405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary tumour expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer.
    Parker BS; Ciocca DR; Bidwell BN; Gago FE; Fanelli MA; George J; Slavin JL; Möller A; Steel R; Pouliot N; Eckhardt B; Henderson MA; Anderson RL
    J Pathol; 2008 Feb; 214(3):337-46. PubMed ID: 17985332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients.
    Ibrahim T; Sacanna E; Gaudio M; Mercatali L; Scarpi E; Zoli W; Serra P; Ricci R; Serra L; Kang Y; Amadori D
    Clin Breast Cancer; 2011 Dec; 11(6):369-75. PubMed ID: 21764390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.
    Ladoire S; Arnould L; Mignot G; Coudert B; Rébé C; Chalmin F; Vincent J; Bruchard M; Chauffert B; Martin F; Fumoleau P; Ghiringhelli F
    Breast Cancer Res Treat; 2011 Jan; 125(1):65-72. PubMed ID: 20229175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of p53, p21 and cyclin D1 in penile cancer: p53 predicts poor prognosis.
    Gunia S; Kakies C; Erbersdobler A; Hakenberg OW; Koch S; May M
    J Clin Pathol; 2012 Mar; 65(3):232-6. PubMed ID: 22135025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Abl interactor 1 and its prognostic significance in breast cancer: a tissue-array-based investigation.
    Wang C; Tran-Thanh D; Moreno JC; Cawthorn TR; Jacks LM; Wang DY; McCready DR; Done SJ
    Breast Cancer Res Treat; 2011 Sep; 129(2):373-86. PubMed ID: 21046228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of osteopontin in patients with triple-negative breast cancer.
    Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
    Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
    Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
    Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
    Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.
    Chang J; Clark GM; Allred DC; Mohsin S; Chamness G; Elledge RM
    Cancer; 2003 Feb; 97(3):545-53. PubMed ID: 12548595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
    Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
    J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.